The Longevity Foundation Stack: Epithalon + Thymalin + GHK-Cu

Research disclaimer: These compounds are sold for research purposes only and are not intended for human consumption.

Evidence Tier for This Combination

Animal studies + human observational data for Epithalon and Thymalin (Khavinson Institute, St. Petersburg). In vitro and animal data for GHK-Cu with some human topical and wound-healing evidence.

This is the strongest-evidenced longevity stack in the research peptide literature — not because the evidence is strong in absolute terms, but because competing options have less. The Khavinson group has published longitudinal data on peptide bioregulator use in elderly human cohorts over periods of 6–15 years. These are observational, not randomised controlled trials, but they represent more human data than most peptides ever accumulate.

Why These Three Work Together

Biological ageing is not a single process. Three of its most documented drivers are: telomere shortening, thymic involution (immune ageing), and declining systemic repair capacity. Each compound in this stack targets a different one.

Epithalon → Telomere Support

Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Vladimir Khavinson from the pineal gland. Its most studied mechanism is telomerase activation — specifically, it has been shown in cell culture and animal models to increase telomerase activity, resulting in telomere elongation. It also regulates melatonin synthesis via the pineal gland, which has downstream effects on circadian rhythm and oxidative stress.

Khavinson’s group published human data showing that elderly patients on multi-year peptide bioregulator protocols had reduced all-cause mortality compared to controls. Epithalon was part of these protocols. The telomere data from human studies is limited but includes measurements showing longer telomeres in treated groups.

Thymalin → Immune Restoration

Thymalin is a thymic peptide extract (containing a mixture of peptide bioregulators including thymosin-like peptides) developed by the same Khavinson group. The thymus begins involuting in early adulthood and is largely inactive by age 40–50. This drives the well-documented decline in T-cell diversity and adaptive immune function with age.

Thymalin’s mechanism is restoration of thymic peptide signalling, promoting T-cell maturation and NK cell activity. In Khavinson’s 6-year elderly cohort studies, Thymalin significantly reduced mortality — the effect size was larger than Epithalon alone. The combination of both was studied and showed additive benefit.

Note: Thymosin Alpha-1 is a specific, sequenced peptide that overlaps in function with Thymalin. If Thymalin (the extract) is not available, Thymosin Alpha-1 is the closest sequenced alternative with its own human clinical data (approved in 35+ countries for immune support).

GHK-Cu → Systemic Repair

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is an endogenous peptide that declines approximately 1,000-fold in plasma concentration between ages 20 and 60. It activates over 30 genes involved in tissue repair, DNA damage response, anti-inflammatory signalling, and tumour suppression pathways. It is also the most accessible peptide in this stack: topical GHK-Cu has a meaningful body of human evidence from wound healing and skin research, including clinical trials.

In the context of a longevity stack, GHK-Cu addresses the decline in systemic repair signalling that is a hallmark of ageing — separate from telomere biology and immune function, but equally well-documented as a driver of age-related deterioration.

Cycle Protocol

Longevity peptides are typically run in cycles rather than continuously. The Khavinson protocols use short, intense cycles 1–2 times per year.

Standard Khavinson-derived cycle:

Epithalon and Thymalin are typically run simultaneously during the same 10-day window, mirroring the Khavinson protocols.

Dosing Table

Timing Within the Day

Epithalon and Thymalin can be administered at the same time. Morning or evening — no strong evidence for timing preference. GHK-Cu as a subcutaneous injection follows the same flexibility.

Topical GHK-Cu (if using the topical route) is typically applied morning and evening to face, neck, or areas of concern. The topical route likely does not produce the same systemic effects as subcutaneous injection, but has the most human evidence of any GHK-Cu delivery method.

What to Expect Realistically

Epithalon and Thymalin: These are not compounds that produce immediate subjective effects. The Khavinson data shows mortality and disease-incidence differences over years, not weeks. In the short term, some researchers report improved sleep quality with Epithalon (via melatonin regulation) and mild immune changes with Thymalin. Do not expect to feel meaningfully different after one cycle.

GHK-Cu: Topical effects on skin quality are the most commonly reported and most evidenced outcome. Systemic effects from subcutaneous injection are harder to observe subjectively. Long-term DNA repair and anti-inflammatory effects are not perceptible in the short run.

The honest framing: This stack is a bet on biology — that restoring declining peptide signals in ageing tissues produces measurable benefit over years, based on the Khavinson longitudinal data. It is not a short-term performance stack. The case for it is preventative, not symptomatic.

Summary

This stack addresses three distinct and well-documented ageing mechanisms through three peptides with more human context than most research peptides. The evidence is not RCT-level — the Khavinson data is observational and was not conducted under Western clinical trial standards. But it represents genuine longitudinal human data rather than pure animal extrapolation.

For researchers interested in longevity biology rather than immediate performance, this combination is the most evidence-grounded starting point in the peptide literature.

See also: Epithalon data page · Thymosin Alpha-1 data page · GHK-Cu data page